USP Names “Key” Drug Types, But Leaves Them Out Of Formulary Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Pharmacopeia is dropping recommended drug class subdivisions from its model guidelines in favor of providing CMS with a list of "formulary key drug types" the agency should consider in reviewing plans for the Medicare Rx program
You may also be interested in...
Medicare Formularies Need One Of Each USP “Key Drug Type,” CMS Says
The Centers for Medicare & Medicaid Services expects Medicare prescription drug plan formularies to include at least one drug from each of U.S. Pharmacopeia's "formulary key drug types" list
Medicare Formularies Need One Of Each USP “Key Drug Type,” CMS Says
The Centers for Medicare & Medicaid Services expects Medicare prescription drug plan formularies to include at least one drug from each of U.S. Pharmacopeia's "formulary key drug types" list
USP's Finalized Model For Medicare Rx Formularies Retains 146 Drug Groups
Overall, the model guidelines resemble the version proposed by USP in August but include revisions to specific therapeutic categories and pharmacologic classes. Proton pump inhibitors are placed in a separate drug class; SSRIs/SNRIs remain off the formal chart.